Suppr超能文献

采用基于生理的药代动力学模型个性化维生素 D。

Personalise vitamin D using physiologically based pharmacokinetic modelling.

机构信息

Beyond Consulting Ltd, Macclesfield, UK.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2021 Jul;10(7):723-734. doi: 10.1002/psp4.12640. Epub 2021 Jun 3.

Abstract

Plasma concentration of vitamin D metabolite 25-hydroxyvitamin D (25(OH)D ) is variable among individuals. The objective of this study is to establish an accurate model for 25(OH)D pharmacokinetics (PKs) to support selection of a suitable dose regimen for an individual. We collated vitamin D and 25(OH)D plasma PK data from reported clinical trials and developed a physiologically-based pharmacokinetic (PBPK) model to appropriately recapitulate training data. Model predictions were then qualified with 25(OH)D plasma PKs under vitamin D and 25(OH)D dose regimens distinct from training data. From data exploration, we observed the increase in plasma 25(OH)D after repeated dosing was negatively correlated with 25(OH)D baseline levels. Our final model included a first-order vitamin D absorption, a first-order vitamin D metabolism, and a nonlinear 25(OH)D elimination function. This structure explained the apparent paradox. Remarkably, the model accurately predicted plasma 25(OH)D following repeated dosing up to 1250 μg/d in the test set. It also made sensible predictions for large single vitamin D doses up to 50,000 μg in the test set. Model predicts 10 μg/d regimen may be ineffective for achieving sufficiency (plasma 25(OH)D ≥ 75 nmol/L) for a severely deficient individual (baseline 25(OH)D = 10 nmol/L), and it might take the same person over 200 days to reach sufficiency at 20 μg/d dose. We propose to personalize vitamin D supplementation protocol with this PBPK model. It would require measuring 25(OH)D baseline levels, which is not routinely performed under the current UK public health advice. STUDY HIGHLIGHTS: WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Vitamin D PK exhibits substantial inter-individual variability. Different officially recommended daily doses are confusing. ​ WHAT QUESTION DID THIS STUDY ADDRESS? Is the UK's recommended 10 µg daily dose sufficient? Should everyone be given same dose? ​ WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? Our model accurately predicts plasma 25(OH)D under daily oral administration of vitamin D . The 10 µg daily vitamin D dose is insufficient for prophylaxis (plasma 25(OH)D at 75 nmol/L). ​ HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS? Combining blood test to measure 25(OH)D baseline with this PBPK model will help inform dosage selection and select follow-up date to improve effectiveness of Hypovitaminosis D treatment.

摘要

个体间维生素 D 代谢产物 25-羟维生素 D(25(OH)D)的血浆浓度存在差异。本研究旨在建立 25(OH)D 药代动力学(PKs)的准确模型,以支持为个体选择合适的剂量方案。我们整理了报告的临床试验中的维生素 D 和 25(OH)D 血浆 PK 数据,并开发了一个基于生理的药代动力学(PBPK)模型,以适当重现训练数据。然后,使用与训练数据不同的维生素 D 和 25(OH)D 剂量方案,对模型预测进行了 25(OH)D 血浆 PK 的验证。从数据探索中,我们观察到重复给药后血浆 25(OH)D 的增加与 25(OH)D 基线水平呈负相关。我们的最终模型包括一阶维生素 D 吸收、一阶维生素 D 代谢和非线性 25(OH)D 消除函数。这种结构解释了明显的悖论。值得注意的是,该模型准确预测了在测试集中高达 1250μg/d 的重复给药后的血浆 25(OH)D。它还对测试集中高达 50,000μg 的大剂量单维生素 D 进行了合理预测。模型预测 10μg/d 的方案可能对严重缺乏的个体(基线 25(OH)D = 10nmol/L)实现充足性(血浆 25(OH)D≥75nmol/L)无效,并且可能需要同一个人超过 200 天才能达到 20μg/d 剂量的充足性。我们建议使用这种 PBPK 模型个性化维生素 D 补充方案。它将需要测量 25(OH)D 基线水平,而根据当前英国公共卫生建议,这并非常规进行。研究重点:关于这个主题,目前有哪些知识?维生素 D PK 表现出显著的个体间变异性。不同的官方推荐日剂量令人困惑。这个研究解决了什么问题?英国推荐的 10μg 日剂量是否足够?是否应该给每个人相同的剂量?这项研究增加了我们的哪些知识?我们的模型准确预测了维生素 D 每日口服给药下的血浆 25(OH)D。每日 10μg 维生素 D 剂量不足以预防(血浆 25(OH)D 为 75nmol/L)。这将如何改变药物发现、开发和/或治疗?将测量 25(OH)D 基线的血液测试与该 PBPK 模型相结合,将有助于告知剂量选择,并选择随访日期,以提高 Hypovitaminosis D 治疗的有效性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f06/8302240/df9c4b270ace/PSP4-10-723-g002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验